Placental Vesicles Carry Active Endothelial Nitric Oxide Synthase and Their Activity is Reduced in Preeclampsia

Carolina Motta-Mejia, Neva Kandzija, Wei Zhang, Vuyane Mhlomi, Ana Sofia Cerdeira, Alexandra Burdujan, Dionne Tannetta, Rebecca Dragovic, Ian L Sargent, Christopher W Redman, Uday Kishore, Manu Vatish, Carolina Motta-Mejia, Neva Kandzija, Wei Zhang, Vuyane Mhlomi, Ana Sofia Cerdeira, Alexandra Burdujan, Dionne Tannetta, Rebecca Dragovic, Ian L Sargent, Christopher W Redman, Uday Kishore, Manu Vatish

Abstract

Preeclampsia, a multisystem hypertensive disorder of pregnancy, is associated with increased systemic vascular resistance. Placentae from patients with preeclampsia have reduced levels of endothelial nitric oxide synthase (eNOS) and, thus, less nitric oxide (NO). Syncytiotrophoblast extracellular vesicles (STBEV), comprising microvesicles (STBMV) and exosomes, carry signals from the syncytiotrophoblast to the mother. We hypothesized that STBEV-bound eNOS (STBEV-eNOS), capable of producing NO, are released into the maternal circulation. Dual-lobe ex vivo placental perfusion and differential centrifugation was used to isolate STBEV from preeclampsia (n=8) and normal pregnancies (NP; n=11). Plasma samples of gestational age-matched preeclampsia and NP (n=6) were used to isolate circulating STBMV. STBEV expressed placental alkaline phosphatase, confirming placental origin. STBEV coexpressed eNOS, but not inducible nitric oxide synthase, confirmed using Western blot, flow cytometry, and immunodepletion. STBEV-eNOS produced NO, which was significantly inhibited by N G-nitro-l-arginine methyl ester (eNOS inhibitor; P<0.05) but not by N-(3-(aminomethyl) bezyl) acetamidine) (inducible nitric oxide synthase inhibitor). STBEV-eNOS catalytic activity was confirmed by visualizing eNOS dimerization. STBEV-eNOS was more abundant in uterine vein compared with peripheral blood, indicating placental origin. STBEV isolated from preeclampsia-perfused placentae had lower levels of STBEV-eNOS (STBMV; P<0.05) and overall lower NO activity (STBMV, not significant; syncytiotrophoblast extracellular exosomes, P<0.05) compared with those from NP. Circulating plasma STBMV from preeclampsia women had lower STBEV-eNOS expression compared with that from NP women (P<0.01). This is the first observation of functional eNOS expressed on STBEV from NP and preeclampsia placentae, as well as in plasma. The lower STBEV-eNOS NO production seen in preeclampsia may contribute to the decreased NO bioavailability in this disease.

Keywords: endothelial nitric oxide synthase; hypertension; nitric oxide; preeclampsia; syncytiotrophoblast extracellular vesicles.

© 2017 The Authors.

Figures

Figure 1.
Figure 1.
Immunohistochemical staining of normal pregnancy (NP) placenta tissue and Western blot of NP and preeclampsia (PE)-derived placental lysate (PL), syncytiotrophoblast extracellular microvesicles (STBMV) and syncytiotrophoblast extracellular exosomes (STBEX; n=3). A, Placental tissue showing endothelial nitric oxide synthase (eNOS) staining (brown; left) on syncytiotrophoblast (STB) layer and IgG2a-negative staining (right). Immunoblot showing eNOS (140 kDa) and placental alkaline phosphatase (PlAP; 60 kDa) expression in PL, STBMV, and STBEX derived from NP (B) and PE (C) similar to expression of positive control, human umbilical vein endothelial cells (HUVEC). D, Placental tissue demonstrating lack of inducible nitric oxide synthases (iNOS) staining (left) and isotype control IgG1-negative staining (right). Immunoblot showing no expression for iNOS (131 kDa) though positive control, RAW, is expressed and PlAP (60 kDa) is also expressed in PL, STBMV, and STBEX derived from NP (E) and PE (F). Scale bar set at 100 mm.
Figure 2.
Figure 2.
Flow cytometry analysis of ex vivo syncytiotrophoblast extracellular microvesicles (STBMV) derived from normal pregnancy (NP) and preeclampsia (PE) placentae (n=6). A, STBMV-bound endothelial nitric oxide synthase (eNOS) expression were significantly lower in PE compared with NP (*P<0.05). Flow cytometry analysis of circulating in vivo STBMV derived from paired peripheral vein blood (PB) and uterine vein blood (UV) plasma (n=8). B, Double-positive eNOS and placental alkaline phosphatase (PlAP) events per milliliter were higher in UV compared with PB (**P<0.01). Flow cytometry analysis of circulating in vivo syncytiotrophoblast extracellular vesicles (STBEV) derived from matched PB plasma of NP and PE patients (n=6). C, PlAP and eNOS double-positive STBMV events per milliliter were significantly lower in plasma from PE compared with NP (**P<0.01). PFP indicates platelet-free plasma.
Figure 3.
Figure 3.
Immunobead depletion and nanoparticle tracking analysis (NTA) profiles of syncytiotrophoblast extracellular microvesicles (STBMV) and syncytiotrophoblast extracellular exosomes (STBEX) pools from normal pregnancy (NP; n=3). A, Representative immunoblot showing endothelial nitric oxide synthase (eNOS) and placental alkaline phosphatase (PlAP) coexpression on STBMV pool (Total) and STBMV pulled out (PO) with anti-eNOS Dynabeads, anti-PlAP Dynabeads, anti-IgG2a Dynabeads (isotype control for eNOS), and anti-IgG1 Dynabeads (isotype control for PlAP). B, Representative NTA size vs number profiles of STBMV pool (solid line), supernatant from post-incubation with anti-eNOS Dynabeads (dashed line) and anti-PlAP Dynabeads (dotted line). C, STBMV pool (solid line), supernatant of post incubation with anti-IgG2a Dynabeads (dashed line) and anti-IgG1 Dynabeads (dotted line). D, Representative immunoblot showing eNOS and PlAP coexpression on STBEX pool (Total) and STBEX PO with anti-eNOS, anti-PlAP, anti-IgG2a, and anti-IgG1 Dynabeads. E, Representative NTA size vs number profiles of STBEX pool alone (solid line), supernatant from post-incubation with anti-eNOS (dashed line) and anti-PlAP (dotted line) Dynabeads. F, STBEX pool (solid line), supernatant of post incubation with anti-IgG2a (dashed line) and anti-IgG1 (dotted line) Dynabeads.
Figure 4.
Figure 4.
Syncytiotrophoblast extracellular microvesicles (STBMV) and syncytiotrophoblast extracellular exosomes (STBEX) express functional endothelial nitric oxide synthase (eNOS) and produce nitric oxide (NO). A, Dimerization of syncytiotrophoblast extracellular vesicles (STBEV) immunoblot image showing eNOS dimer (260 kDa) and eNOS monomer (140 kDa) expressed in human umbilical vein endothelial cells (HUVEC), STBMV, and STBEX (n=3). B, STBMV (***P<0.001) and STBEX (***P<0.001) pools showed NO production in a dose-dependent manner (n=6). C, 25 μg pool of STBMV and STBEX preincubated for 1 hour with 1 mmol/L of NG-nitro-l-arginine methyl ester (L-NAME), NOS inhibitor, showed significant reductions in NO production compared with controls (both *P<0.05; n=3). D, 25 μg pool of STBMV and STBEX preincubated for 1 hour with 2 μmol/L N-(3-(aminomethyl) bezyl) acetamidine) (1400W), inducible nitric oxide synthases (iNOS)–specific inhibitor, showed no changes in NO production compared with controls (both ns; n=3).
Figure 5.
Figure 5.
Nitric oxide synthase (NOS) activity of syncytiotrophoblast extracellular microvesicles (STBMV) and syncytiotrophoblast extracellular exosomes (STBEX) isolated from perfused normal pregnancy (NP) and preeclampsia (PE) placentae (n=11 and n=8, respectively). STBMV (A) from PE placentae showed a no overall reduction in NO production compared with NP (ns; P=0.2416). Analysis of the same data as a function of the gestational age of the samples (B) shows a decrease in NO production in samples closest in gestational age to controls (PE>34 weeks vs NP<40 weeks; *P<0.05). While STBEX (C) from PE showed a significant reduction in NO production compared with NP (*P<0.05). This decrease was maintained in samples closest in gestational age to controls (D).

References

    1. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation. 2014;130:1003–1008. doi: 10.1161/CIRCULATIONAHA.114.009029.
    1. WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. World Health Organization; 2011.
    1. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447–1451.
    1. Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia—two placental causes of preeclampsia? Placenta. 2014;35(suppl):S20–S25. doi: 10.1016/j.placenta.2013.12.008.
    1. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1):499–506.
    1. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol. 1997;272(2 pt 2):R441–R463.
    1. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension. 1990;16:477–483.
    1. Shah DA, Khalil RA. Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochem Pharmacol. 2015;95:211–226. doi: 10.1016/j.bcp.2015.04.012.
    1. Ashworth JR, Warren AY, Johnson IR, Baker PN. Plasma from pre-eclamptic women and functional change in myometrial resistance arteries. Br J Obstet Gynaecol. 1998;105:459–461.
    1. Hayman R, Warren A, Johnson I, Baker P. Inducible change in the behavior of resistance arteries from circulating factor in preeclampsia: an effect specific to myometrial vessels from pregnant women. Am J Obstet Gynecol. 2001;184:420–426. doi: 10.1067/mob.2001.109733.
    1. English FA, McCarthy FP, McSweeney CL, Quon AL, Morton JS, Sawamura T, Davidge ST, Kenny LC. Inhibition of lectin-like oxidized low-density lipoprotein-1 receptor protects against plasma-mediated vascular dysfunction associated with pre-eclampsia. Am J Hypertens. 2013;26:279–286. doi: 10.1093/ajh/hps035.
    1. Khalil A, Hardman L, O Brien P. The role of arginine, homoarginine and nitric oxide in pregnancy. Amino Acids. 2015;47:1715–1727. doi: 10.1007/s00726-015-2014-1.
    1. Myatt L, Brockman DE, Eis AL, Pollock JS. Immunohistochemical localization of nitric oxide synthase in the human placenta. Placenta. 1993;14:487–495.
    1. Conrad KP, Vill M, McGuire PG, Dail WG, Davis AK. Expression of nitric oxide synthase by syncytiotrophoblast in human placental villi. FASEB J. 1993;7:1269–1276.
    1. Buttery LD, McCarthy A, Springall DR, Sullivan MH, Elder MG, Michel T, Polak JM. Endothelial nitric oxide synthase in the human placenta: regional distribution and proposed regulatory role at the feto-maternal interface. Placenta. 1994;15:257–265.
    1. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991;12:301–308.
    1. Maltepe E, Fisher SJ. Placenta: the forgotten organ. Annu Rev Cell Dev Biol. 2015;31:523–552. doi: 10.1146/annurev-cellbio-100814-125620.
    1. Sarker S, Scholz-Romero K, Perez A, Illanes SE, Mitchell MD, Rice GE, Salomon C. Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J Transl Med. 2014;12:204. doi: 10.1186/1479-5876-12-204.
    1. Salomon C, Torres MJ, Kobayashi M, Scholz-Romero K, Sobrevia L, Dobierzewska A, Illanes SE, Mitchell MD, Rice GE. A gestational profile of placental exosomes in maternal plasma and their effects on endothelial cell migration. PLoS One. 2014;9:e98667. doi: 10.1371/journal.pone.0098667.
    1. Tannetta DS, Dragovic RA, Gardiner C, Redman CW, Sargent IL. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin. PLoS One. 2013;8:e56754. doi: 10.1371/journal.pone.0056754.
    1. Tong M, Chamley LW. Placental extracellular vesicles and feto-maternal communication. Cold Spring Harb Perspect Med. 2015;5:a023028. doi: 10.1101/cshperspect.a023028.
    1. Dragovic RA, Collett GP, Hole P, Ferguson DJ, Redman CW, Sargent IL, Tannetta DS. Isolation of syncytiotrophoblast microvesicles and exosomes and their characterisation by multicolour flow cytometry and fluorescence Nanoparticle Tracking Analysis. Methods. 2015;87:64–74. doi: 10.1016/j.ymeth.2015.03.028.
    1. Dragovic RA, Southcombe JH, Tannetta DS, Redman CW, Sargent IL. Multicolor flow cytometry and nanoparticle tracking analysis of extracellular vesicles in the plasma of normal pregnant and pre-eclamptic women. Biol Reprod. 2013;89:151. doi: 10.1095/biolreprod.113.113266.
    1. Inglis HC, Danesh A, Shah A, Lacroix J, Spinella PC, Norris PJ. Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. Cytometry A. 2015;87:1052–1063. doi: 10.1002/cyto.a.22649.
    1. Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, Heales S, Channon KM. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res. 2002;55:838–849.
    1. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, Knowles RG. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem. 1997;272:4959–4963.
    1. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia. 2005;48:1933–1940. doi: 10.1007/s00125-005-1857-5.
    1. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol. 1994;171:944–948.
    1. Burke SD, Zsengellér ZK, Khankin EV, et al. Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. J Clin Invest. 2016;126:2561–2574. doi: 10.1172/JCI83918.
    1. Conrad KP, Davis AK. Nitric oxide synthase activity in placentae from women with pre-eclampsia. Placenta. 1995;16:691–699.
    1. Kakui K, Sagawa N, Itoh H, Yura S, Korita D, Takemura M, Nuamah MA, Fujii S. Expression of nitric oxide synthase isoforms in the human placenta is not altered by labor. Endocr J. 2003;50:535–544.
    1. Schiessl B, Mylonas I, Hantschmann P, Kuhn C, Schulze S, Kunze S, Friese K, Jeschke U. Expression of endothelial NO synthase, inducible NO synthase, and estrogen receptors alpha and beta in placental tissue of normal, preeclamptic, and intrauterine growth-restricted pregnancies. J Histochem Cytochem. 2005;53:1441–1449. doi: 10.1369/jhc.4A6480.2005.
    1. Schiessl B, Mylonas I, Kuhn C, Kunze S, Schulze S, Friese K, Jeschke U. Expression of estrogen receptor-alpha, estrogen receptor-beta and placental endothelial and inducible NO synthase in intrauterine growth-restricted and normal placentals. Arch Med Res. 2006;37:967–975. doi: 10.1016/j.arcmed.2006.03.011.
    1. Zarlingo TJ, Eis AL, Brockman DE, Kossenjans W, Myatt L. Comparative localization of endothelial and inducible nitric oxide synthase isoforms in haemochorial and epitheliochorial placentae. Placenta. 1997;18:511–520.
    1. Lyall F. Development of the utero-placental circulation: the role of carbon monoxide and nitric oxide in trophoblast invasion and spiral artery transformation. Microsc Res Tech. 2003;60:402–411. doi: 10.1002/jemt.10278.
    1. Yoshida T, Limmroth V, Irikura K, Moskowitz MA. The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. J Cereb Blood Flow Metab. 1994;14:924–929. doi: 10.1038/jcbfm.1994.123.
    1. Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol. 2002;187:1686–1693.
    1. Shomer E, Katzenell S, Zipori Y, Sammour RN, Isermann B, Brenner B, Aharon A. Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension. 2013;62:893–898. doi: 10.1161/HYPERTENSIONAHA.113.01494.
    1. Horn P, Cortese-Krott MM, Amabile N, Hundsdörfer C, Kröncke KD, Kelm M, Heiss C. Circulating microparticles carry a functional endothelial nitric oxide synthase that is decreased in patients with endothelial dysfunction. J Am Heart Assoc. 2012;2:e003764. doi: 10.1161/JAHA.112.003764.
    1. Kao CK, Morton JS, Quon AL, Reyes LM, Lopez-Jaramillo P, Davidge ST. Mechanism of vascular dysfunction due to circulating factors in women with pre-eclampsia. Clin Sci (Lond) 2016;130:539–549. doi: 10.1042/CS20150678.
    1. Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost. 2009;7:375–384. doi: 10.1111/j.1538-7836.2008.03259.x.
    1. O’ Kane PD, Jackson G, Ferro A. Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteine. Atherosclerosis. 2008;196:574–579.
    1. Heiss C, Schanz A, Amabile N, Jahn S, Chen Q, Wong ML, Rassaf T, Heinen Y, Cortese-Krott M, Grossman W, Yeghiazarians Y, Springer ML. Nitric oxide synthase expression and functional response to nitric oxide are both important modulators of circulating angiogenic cell response to angiogenic stimuli. Arterioscler Thromb Vasc Biol. 2010;30:2212–2218. doi: 10.1161/ATVBAHA.110.211581.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi